Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a report published on Friday.

Several other analysts have also weighed in on SUPN. Weiss Ratings reiterated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research note on Saturday, September 27th. Piper Sandler boosted their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a “neutral” rating in a research note on Friday, August 29th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. Finally, Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Supernus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $51.50.

Supernus Pharmaceuticals Price Performance

SUPN opened at $48.35 on Friday. The stock has a market capitalization of $2.71 billion, a PE ratio of 42.04 and a beta of 0.78. The firm’s fifty day moving average price is $43.52 and its 200 day moving average price is $36.11. Supernus Pharmaceuticals has a 12-month low of $29.16 and a 12-month high of $49.66.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 14,000 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.51, for a total transaction of $623,140.00. Following the completion of the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $689,726.96. This represents a 47.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Timothy C. Dec sold 11,780 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the transaction, the chief financial officer owned 1,246 shares of the company’s stock, valued at $55,434.54. This represents a 90.43% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 302,841 shares of company stock valued at $13,361,449. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Armistice Capital LLC grew its position in Supernus Pharmaceuticals by 7.4% in the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company’s stock valued at $170,169,000 after buying an additional 360,000 shares in the last quarter. State Street Corp grew its position in Supernus Pharmaceuticals by 2.9% in the 2nd quarter. State Street Corp now owns 2,208,560 shares of the specialty pharmaceutical company’s stock valued at $69,614,000 after buying an additional 63,210 shares in the last quarter. Geode Capital Management LLC grew its position in Supernus Pharmaceuticals by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,399,610 shares of the specialty pharmaceutical company’s stock valued at $44,121,000 after buying an additional 72,991 shares in the last quarter. GW&K Investment Management LLC grew its position in Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company’s stock valued at $45,275,000 after buying an additional 176,091 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its position in Supernus Pharmaceuticals by 53.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock valued at $25,192,000 after buying an additional 278,575 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.